别名 Beta-hexosaminidase、Beta-N-acetylglucosaminidase、Beta-N-acetylhexosaminidase + [13] |
简介 Cleaves GlcNAc but not GalNAc from O-glycosylated proteins (PubMed:11148210, PubMed:11788610, PubMed:20673219, PubMed:22365600, PubMed:24088714, PubMed:28939839, PubMed:37962578). Deglycosylates a large and diverse number of proteins, such as CRYAB, ELK1, GSDMD, LMNB1 and TAB1 (PubMed:28939839, PubMed:37962578). Can use p-nitrophenyl-beta-GlcNAc and 4-methylumbelliferone-GlcNAc as substrates but not p-nitrophenyl-beta-GalNAc or p-nitrophenyl-alpha-GlcNAc (in vitro) (PubMed:20673219). Does not bind acetyl-CoA and does not have histone acetyltransferase activity (PubMed:24088714).
Cleaves GlcNAc but not GalNAc from O-glycosylated proteins. Can use p-nitrophenyl-beta-GlcNAc as substrate but not p-nitrophenyl-beta-GalNAc or p-nitrophenyl-alpha-GlcNAc (in vitro), but has about six times lower specific activity than isoform 1. |
作用机制 APP抑制剂 [+2] |
原研机构 |
非在研适应症- |
最高研发阶段临床2/3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 OGA抑制剂 |
在研机构 |
原研机构 |
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 OGA抑制剂 |
在研适应症 |
非在研适应症- |
最高研发阶段临床申请 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2023-02-24 |
申办/合作机构 |
开始日期2022-01-24 |
申办/合作机构 |